Skip to main content

Ewing's Tumor Recurrent clinical trials at UC Health

1 in progress, 0 open to eligible people

Showing trials for
  • Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma

    Sorry, in progress, not accepting new patients

    This is a multicenter, 1:1 randomized Phase III study of intradermal autologous Vigil immunotherapy (1.0 x 10e6 cells/injection; minimum of 4 to a maximum of 12 administrations) in combination with irinotecan and temozolomide in subjects with metastatic Ewing's sarcoma Family of Tumors (ESFT) refractory/intolerant or recurrent to 1 prior line of chemotherapy. Participants undergoing a standard surgical procedure (e.g., tumor biopsy or palliative resection) may have tumor tissue harvested for manufacture of the investigational product, Vigil.

    at UCLA

Last updated: